Elephantiasis, Filarial clinical trials
The registry lists 42 studies for Elephantiasis, Filarial across more than 10 countries. 5 are recruiting or about to start. 29 of them are mainly about Elephantiasis, Filarial (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-07.
Get an email when these change. Save the Elephantiasis, Filarial studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Washington University School of Medicine (9) · University Hospitals Cleveland Medical Center (5) · National Institute of Allergy and Infectious Diseases (NIAID) (4) · London School of Hygiene and Tropical Medicine (4) · The Task Force for Global Health (3) · Noguchi Memorial Institute for Medical Research (2) · Liverpool School of Tropical Medicine (2) · Lihir Medical Centre (2)
What is being tested here
Drugs under test in Elephantiasis, Filarial studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 3, phase 3 first
- Jun 2027Better Options for Lymphatic Filariasis Treatment · Phase 3 · Medicines Development for Global Health
- Feb 2027Integrating Mental Health Into Neglected Tropical Disease Care in Ghana · Liverpool School of Tropical Medicine
- Jul 2027Expanding Access to Preventive Chemotherapy Among Mobile and Migrant Populations · Uwemedimo Friday Ekpo
Who these studies take
Of the 3 Elephantiasis, Filarial studies recruiting now, 2 (67%) set no upper age limit and 1 (33%) stop at 75 or younger. 3 (100%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 3 (100%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 3 (100%) | 3 (100%) |
| 18 | 3 (100%) | 3 (100%) |
| 30 | 3 (100%) | 3 (100%) |
| 40 | 3 (100%) | 3 (100%) |
| 50 | 3 (100%) | 3 (100%) |
| 65 | 3 (100%) | 3 (100%) |
| 75 | 3 (100%) | 3 (100%) |
| 85 | 2 (67%) | 2 (67%) |
Across all 42 studies, recruiting or not: 43% stop at 75 or younger and 36% at 65; 64% take children; 0% are for women only and 0% for men only; 62% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 42 of 42. search them.
- Better Options for Lymphatic Filariasis TreatmentRecruitingNCT07159373Phase 31 country
- Expanding Access to Preventive Chemotherapy Among Mobile and Migrant PopulationsRecruitingNCT07707817Not applicable1 country
- Early Detection and AI-Based Management of Skin-Related Neglected Tropical Diseases in Sub-Saharan Africa by Frontline Health WorkersNot yet recruitingNCT07506967Not applicable5 countries
- Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health PerspectiveRecruitingNCT073589101 country
- Integrating Mental Health Into Neglected Tropical Disease Care in GhanaNot yet recruitingNCT07248462Not applicable
- Spontaneous Antigenemia in LoiasisCompletedNCT042586701 country
- Moxidectin for LF, Cote d'Ivoire (DOLF)CompletedNCT04410406Phase 31 country
- East New Britain Province Monitoring & EvaluationCompletedNCT041242501 country
- Integrated Mapping of Skin-presenting Neglected Tropical Diseases in LiberiaCompletedNCT036837451 country
- Development of AWZ1066S, a Small Molecule Anti-Wolbachia Candidate Macrofilaricide DrugTerminatedNCT05084560Phase 11 country
- Cluster RCT of Co-administration Azithromycin, Albendazole & IvermectinCompletedNCT03570814Phase 41 country
- Lymphatic Filariasis (LF) in Ivory CoastCompletedNCT02974049Not applicable1 country
- Adjunctive Ivermectin Mass Drug Administration for Malaria ControlStatus unknownNCT04844905Phase 31 country
- Mass Drug Administration for Lymphatic Filariasis and Onchocerciasis for LiberiaCompletedNCT019054361 country
- A 24 Month Study, to Compare the Efficacy of Doxycycline vs. Placebo for Improving Filarial Lymphedema in MaliCompletedNCT02927496Phase 31 country
- A 24 Month Study to Compare Efficacy of Doxycycline vs Placebo for Improving Filarial Lymphedema in IndiaCompletedNCT02929121Phase 31 country
- A 24 Month Study to Compare Efficacy of Doxycycline vs Placebo for Improving Filarial Lymphedema in Sri LankaCompletedNCT02929134Phase 31 country
- Prevalence Studies After Triple Drug Therapy for Lymphatic FilariasisCompletedNCT033522065 countries
- Death to Onchocerciasis and Lymphatic Filariasis (DOLF) Triple Drug Therapy for Lymphatic FilariasisCompletedNCT02899936Not applicable4 countries
- Fiji Integrated Therapy (FIT) - Triple Therapy for Lymphatic Filariasis, Scabies and Soil Transmitted Helminths in FijiCompletedNCT03177993Not applicable1 country
- Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and OnchocerciasisCompletedNCT019054231 country
- Twice Yearly Treatment for the Control of LFCompletedNCT03036059Phase 41 country
- Pharmacokinetics & Pharmacodynamics of Diethylcarbamazine (DEC)+ Albendazole (ALB) + Ivermectin (IVE)CompletedNCT02845713Phase 11 country
- Optimization of MDA With Existing Drug Regimens for LF: Monitoring Efficacy of Ongoing Treatment Programs in PNGCompletedNCT032682521 country
- Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs )CompletedNCT03676140Phase 31 country
- PK PD Study of IDA and Azithromycin for NTDs ( ComboNTDs )CompletedNCT03664063Phase 21 country
- Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy StudyCompletedNCT02509481Phase 2/32 countries
- Prevalence of LF Infection in Districts Not Included in LF Control ActivitiesCompletedNCT031314011 country
- Eval 3-Drug Therapy Diethylcarbamize, Albendazole and Ivermectin That Could Accelerate LF Elimination Outside of AfricaCompletedNCT01975441Phase 21 country
- Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast (DOLF-Ivory Coast)CompletedNCT020320431 country
- Effect of Albendazole Dose on Clearance of Filarial WormsCompletedNCT00339417Phase 21 country
- Changes in HIV Viral Load in Patients Undergoing Treatment for FilariasisCompletedNCT003442791 country
- Effect of Albendazole Dose on Clearance of Filarial WormsCompletedNCT00375583Phase 21 country
- Impact of Albendazole -Ivermectin on Wuchereria Bancrofti in MaliCompletedNCT02784743Phase 4
- Effect of Albendazole Dose on Treatment of Lymphatic FilariasisCompletedNCT00511004Phase 21 country
- Efficacy of Higher Albendazole and Ivermectin Doses on Wuchereria Bancrofti Microfilarial Clearance in MalawiTerminatedNCT01213576Not applicable1 country
- Safety Study of Combined Azithromycin, Ivermectin and Albendazole for Trachoma and Lymphatic FilariasisWithdrawnNCT01903057Phase 41 country
- Disability and Quality of Life in Patients With Lymphatic Filariasis in Rural Southern IndiaCompletedNCT016297712 countries
- Alternate Chemotherapy Regimens for the Clearance of W.Bancrofti InfectionCompletedNCT02005653Phase 41 country
- Safety of the Co-administration of Three Drugs for Trachoma and Lymphatic Filariasis EliminationCompletedNCT01586169Not applicable1 country
- Research for Elimination of Lymphatic Filariasis (ICIDR)CompletedNCT004066271 country
- Interaction Between HIV and Lymphatic FilariasisCompletedNCT00295698Not applicable